I'll ask Brigitte to complement my answer.
When companies decide where to invest and bring jobs, they consider a number of factors: infrastructure, quality of the research, access to the health care system, and a number of other factors. IP is one of them.
The size of the market is important, too. Canada is a relatively small market. We want an equal IP regime. All we are asking for is an equalized playing field to give our Canadian CEOs, those champions that have to battle at their head offices for those research dollars, another tool to win some of those contracts.
The announcement at Roche of $200 million, which Brigitte will talk about, I don't want to be the exception. I want it to be the rule. I would like the $1.3 billion we invest right now to grow, and to grow as large as it can. IP will help us do that. Without it, companies will say, yes, we have good infrastructure and, yes, we have good scientists, but we don't have the IP to protect that research.